Abstract
The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8%) and other severe diseases (38.9%).
| Bidragets oversatte titel | Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group. |
|---|---|
| Originalsprog | Engelsk |
| Tidsskrift | European Heart Journal |
| Vol/bind | 14 |
| Udgave nummer | 3 |
| Sider (fra-til) | 377-379 |
| Antal sider | 3 |
| ISSN | 0195-668X |
| Status | Udgivet - 1993 |